Amyris & Ginkgo Bioworks Complete Collaboration Agreement to Accelerate Commercialization of Bio-Based Products
September 15 2016 - 8:30AM
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company,
today announced that it has completed a subsequent collaboration
agreement with Ginkgo Bioworks, which is expected to be approved by
the boards of both companies. The agreement finalizes details of
how the two companies will jointly develop cultured products more
efficiently and cost effectively, accelerating time to market. This
breakthrough biotech collaboration was initially announced on June
29, 2016 and, upon board approval, both companies plan to move
quickly to establish a leading position within the market for
sustainable, bio-based products.
Per the agreement, Ginkgo and Amyris will share in the value of
new cultured ingredients brought to market across several
industries including food and nutrition, flavor and fragrance, and
cosmetics and personal care. These ingredients, produced via
fermentation with engineered microorganisms, leverage the
end-to-end biotechnology stack that Ginkgo and Amyris have
developed, from high throughput automated strain development,
analytics, and optimization, to process development, full-scale
manufacturing, and product recovery operations.
“Working together with Ginkgo leverages our combined strengths
to make renewable products mainstream. The combination of our
capabilities creates an unparalleled offer for partners who want to
create competitive advantage in their supply chain. We’re
very pleased with our continued execution this year and remain on
track for expected record revenue in the third quarter of 2016, and
execution on the non-core asset sales that are expected to deliver
strong, positive cash flow by year end,” said John Melo, President
and CEO of Amyris.
Continued Melo, “We are pleased with the early results of this
collaboration. With what we believe is the world’s largest combined
R&D groups focused on engineering organisms and producing
cultured ingredients at robust industrial manufacturing scale, we
are able to offer our customers the best solution in the
market.”
“We’re delighted with the collaborative effort our teams have
already shown in reviewing key areas where both companies can excel
together,” said Jason Kelly, CEO of Ginkgo Bioworks. “This should
lead to more efficiency in bringing new products to market for our
partners more quickly by utilizing the top-notch engineering talent
of both companies along with Ginkgo’s foundries and Amyris’s
manufacturing expertise.”
About Amyris
Amyris is the integrated renewable products company that is
enabling the world’s leading brands to achieve sustainable growth.
Amyris applies its innovative bioscience solutions to convert plant
sugars into hydrocarbon molecules, specialty ingredients and
consumer products. The company is delivering its No Compromise®
products in focused markets, including specialty and performance
chemicals, fragrance ingredients, and cosmetic emollients. More
information about the company is available
at www.amyris.com.
About Ginkgo Bioworks
Headquartered in Boston, Ginkgo Bioworks uses the most advanced
technology on the planet— biology — to grow products instead of
manufacture them. The company’s technology platform is bringing
biotechnology into consumer goods markets-- enabling fragrance,
cosmetic, nutrition, and food companies to make better products.
For more information, visit www.ginkgobioworks.com.
Forward-Looking Statements
This release contains forward-looking statements, and any
statements other than statements of historical fact could be deemed
to be forward-looking statements. These forward-looking statements
include, among other things, statements regarding future events
(such as the expectation that the collaboration agreement will be
approved by the board of directors of both companies, anticipated
record revenue on a quarterly basis for third-quarter 2016, the
expected timing and execution of one or more non-core asset sales,
the expected achievement of positive cash flow by year end, the
expected ability of the companies to jointly develop products more
efficiently and cost effectively under the collaboration,
accelerating time to market, the anticipated competitive
positioning of the companies as a result of the collaboration, as
well as the ability of the collaboration to enable partners to
bring products to market more quickly) that involve risks and
uncertainties. These statements are based on management’s current
expectations and actual results and future events may differ
materially from such expectations due to risks and uncertainties,
including, among other things, Amyris’s liquidity and ability to
fund operating and capital expenses, timing and execution risks
associated with manufacturing, potential delays or failures in
development, production and commercialization of products, Amyris’s
reliance on third parties to achieve its goals, and other risks
detailed in the “Risk Factors” section of Amyris’s quarterly report
on Form 10-Q filed on August 9, 2016. Amyris disclaims any
obligation to update information contained in these forward-looking
statements whether as a result of new information, future events,
or otherwise.
The reference above in regard to expected record revenue in the
third quarter of 2016 excludes historical quarters when the company
had engaged in ethanol sales and trading.
Amyris and the Amyris logo are registered trademarks of Amyris,
Inc. All other trademarks are the property of their respective
owners.
Note to Editors: Please see news release issued June 29, 2016,
entitled, “Ginkgo Bioworks and Amyris Partner to Accelerate
Commercialization of Bio-Based Products”
Contacts:
Grace Emery
Ginkgobioworks@bateman-group.com
+1 (347) 230-6640
Amyris:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
investor@amyris.com
pr@amyris.com
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Apr 2023 to Apr 2024